Abbott P/E Ratio
Current P/E Ratio
35.44
High Valuation
Very High - High growth expectations or significantly overvalued
Abbott (ABBOTINDIA) P/E ratio is 35.44 (High), EPS (TTM) ₹665.62, current price ₹25435.00 on NSE — Very High - High growth expectations or significantly overvalued. For live price, revenue and the complete fundamental profile, see ABBOTINDIA stock overview.
Current Valuation Metrics
P/E Ratio
35.44
Current Price
₹25435.00
EPS (TTM)
₹665.62
Exchange
NSE
Valuation Signal
Signal
Overvalued
Sector Context
Sector Average
53.75
Sector Median
27.43
Sector Rank
#11 of 192
Sector Percentile
5.7%
ABBOTINDIA P/E Ratio — Valuation Signal & Historical Context
Abbott P/E 35.44 — signal: Overvalued. Check Abbott networth to track the company's total market size over time.
- Stock appears overvalued with PE of 35.44, suggesting caution for new investments
- Trading at discount to sector average PE of 53.75
ABBOTINDIA vs Healthcare Peers — P/E Ratio Comparison
Abbott P/E 35.44 vs Healthcare average 53.75, median 27.43 — range 1.03–1007.14.
Sector Average
53.75
Sector Median
27.43
Lowest P/E
1.03
Highest P/E
1007.14
Companies
192
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Welcure Drugs & Pharmace… | WELCURE | 1.03 | ₹36 | Low |
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Phaarmasia | PHRMASI | 4.19 | ₹71 | Low |
| Ind Swift Laboratories | INDSWFTLAB | 4.7 | ₹1,105 | Low |
| Amwill Health Care | AMWILL | 6.71 | ₹71 | Low |
| Shelter Pharma | SHELTER | 6.75 | ₹49 | Low |
| Mono Pharmacare | MONOPHARMA | 7.44 | ₹23 | Low |
| Zenith Drugs | ZENITHDRUG | 7.69 | ₹68 | Low |
| Par Drugs & Chemical | PAR | 8.09 | ₹113 | Low |
| Galaxy Medicare | GML | 8.65 | ₹29 | Low |